Cas:281678-73-7 5-bromo-2,3-dihydro-1-benzofuran-7-carbaldehyde manufacturer & supplier

Chemical Name:5-bromo-2,3-dihydro-1-benzofuran-7-carbaldehyde

CAS.NO:281678-73-7

Synonyms:5-bromo-2,3-dihydrobenzo[b]furan-7-carboaldehyde;5-Bromo-2,3-dihydrobenzo[b]furan-7-carbaldehyde;5-Bromo-2,3-dihydrobenzofuran-7-carbaldehyde

Molecular Formula:C₉H₇BrO₂

Molecular Weight:227.05500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:330.1ºC at 760mmHg

Density:1.652g/cm3

Index of Refraction:1.645

PSA:26.30000

Exact Mass:225.96300

LogP:2.19650

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-bromo-2,3-dihydrobenzo[b]furan-7-carboaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Bromo-2,3-dihydrobenzofuran-7-carbaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Bromo-2,3-dihydrobenzofuran-7-carbaldehyde Use and application,5-bromo-2,3-dihydrobenzo[b]furan-7-carboaldehyde technical grade,usp/ep/jp grade.

Related News: The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 5-bromo-2,3-dihydro-1-benzofuran-7-carbaldehyde manufacturer Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). 5-bromo-2,3-dihydro-1-benzofuran-7-carbaldehyde supplier Delta said it will suspend flights between the United States and China starting on Sunday until at least April 30, according to a press release. 5-bromo-2,3-dihydro-1-benzofuran-7-carbaldehyde vendor The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 5-bromo-2,3-dihydro-1-benzofuran-7-carbaldehyde factory Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday.